NCT02562430View on ClinicalTrials.gov

Neurobiological Underpinnings of Placebo Response in Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Depression
Interventions
DRUG

Welbutrin XL

12.5% of participants will receive Welbutrin XL in phase 1 of the study.

DRUG

Placebo

87.5% of subjects will be randomized to placebo in phase 1 of the study.

Trial Locations (1)

02114

Depression Clinical and Research Program at Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT02562430 - Neurobiological Underpinnings of Placebo Response in Depression | Biotech Hunter | Biotech Hunter